Bayer AG has officially opened a $44 million expansion at its manufacturing site in Myerstown, Pennsylvania. The new 70,000-square-foot annex enhances Bayer’s Consumer Health production capabilities, reinforcing the company’s commitment to delivering trusted self-care solutions throughout North America.

The expansion follows a major investment announced in 2022 and underscores Bayer’s broader strategy to support long-term growth in the region. The Myerstown facility, which has operated for over 75 years, is now the largest manufacturing site in Bayer’s global Consumer Health network. It produces iconic brands such as Bayer Aspirin, Aleve, Claritin, One A Day, Alka-Seltzer Plus, and Midol.

“Our trusted brands have supported healthy living for generations,” said Dave Tomasi, president of Bayer’s Consumer Health division in North America. “This annex allows us to bring our science-backed products to market faster and more reliably. It’s a critical step in advancing our commitment to safe, effective and high-quality self-care solutions.”

The ribbon-cutting event brought together Bayer leadership, employees, elected officials, and community members to celebrate the milestone. The new addition features eight advanced product packaging lines and modernized logistics systems, designed to improve efficiency and responsiveness to evolving consumer needs.

In addition to physical upgrades, Bayer is investing in workforce development. The company is focused on equipping employees with digital skills necessary for success in modern manufacturing. It also plans to engage with local educators by hosting tours of the facility, aiming to share insights and promote STEM education in local school districts.

“We believe our people are the foundation of our growth,” said Divakar Amin, vice president and site manager of the Myerstown facility. “By upskilling our workforce and creating new opportunities, we’re helping build a vibrant future for both Bayer and the local community.”

This investment in Myerstown follows the completion of Bayer’s first Cell Therapy Launch Facility in Berkeley, California, in 2023, further demonstrating the company’s strategic focus on strengthening its presence in North America.

“Our mission of ‘Health for all, Hunger for none’ guides everything we do,” said Michael Sullivan, senior vice president of product supply for Bayer’s Consumer Health division in North America. “This expansion represents not just a commitment to innovation and quality, but to ensuring more people have access to the health solutions they need.”

With its blend of cutting-edge technology, workforce development and community engagement, Bayer’s Myerstown expansion positions the company to meet growing demand while continuing to support local economic growth.